According to a study published in The Lancet Psychiatry on Wednesday, semaglutide, the active ingredient in GLP-1 medications such as Ozempic and Wegovy, is associated with a 42% lower risk of worsening mental illness compared with periods of non-use.
Study: GLP-1 drugs Linked to 42% Lower Mental Illness Risk